Definitive results: IL-2 does not benefit HIV-infected patients. Interleukin-2 improves CD4-cell recovery in patients on antiretroviral therapy, but that benefit does not translate into lower risks for disease or death.
{"title":"Definitive results: IL-2 does not benefit HIV-infected patients. Interleukin-2 improves CD4-cell recovery in patients on antiretroviral therapy, but that benefit does not translate into lower risks for disease or death.","authors":"Charles B Hicks","doi":"10.1056/AC201001040000006","DOIUrl":null,"url":null,"abstract":"For years, researchers have tried to find ways to incorporate interleukin (IL)-2 into HIV management, given its positive effects on CD4-cell counts. However, two large trials this year — SILCAAT and ESPRIT — demonstrated that those positive effects do not translate into …","PeriodicalId":88277,"journal":{"name":"Journal watch. AIDS clinical care","volume":"3 1","pages":"4"},"PeriodicalIF":0.0000,"publicationDate":"2010-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal watch. AIDS clinical care","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1056/AC201001040000006","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
For years, researchers have tried to find ways to incorporate interleukin (IL)-2 into HIV management, given its positive effects on CD4-cell counts. However, two large trials this year — SILCAAT and ESPRIT — demonstrated that those positive effects do not translate into …
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
